TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23256542
Drug: 17-allyamino-17-demethoxygeldanamycin (17-AAG)
Normalized name: 2,4-Bis(allylamino)-6-(4-(bis(p-fluorophenyl)methyl)-1-piperazinyl)-s-triazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17-allyamino-17-demethoxygeldanamycin (17-AAG) in combination with bortezomib
Study: 23256542
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 17-AAG and bortezomib
Study: 23259667
Drug: Docetaxel (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (100 mg/m², 3qw, 6 courses)
Study: 23259667
Drug: DTC-status before
Normalized name: Statuss Green Reformulated Jan 2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTC-status before and after docetaxel treatment
Study: 23261356
Drug: Selumetinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selumetinib (50 mg twice daily, orally) until progression
Study: 23265285
Drug: Albuterol sulfate
Normalized name: Albuterol Sulfate
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol sulfate hydrofluoroalkane (HFA) metered-dose inhaler with integrated dose counter, 90 micrograms, twice-daily dosing for 5 or 7 weeks
Study: 23265712
Drug: Intravenous bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous bevacizumab (5mg/kg every 14 days) and oral rapamycin (1-6 mg/day)
Study: 23267529
Drug: Telehealth problem-solving
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telehealth problem-solving therapy (PST)
Study: 23269537
Drug: Sunitinib 37.5
Normalized name: sunitinib 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 37.5 mg/day on a continuous daily dosing (CDD) schedule
Study: 23269861
Drug: Prucalopride 2
Normalized name: prucalopride 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prucalopride 2 mg (single oral dose)
Study: 23269986
Drug: Adjuvant procarbazine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy
Study: 23270487
Drug: Miglustat 100
Normalized name: miglustat 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miglustat 100 mg t.i.d.
Study: 23270493
Drug: Sitagliptin 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 600 mg orally days -1 to +2
Study: 23272643
Drug: Diammine silver
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diammine silver fluoride (DSF) applied to 3 teeth, mean amount 7.57 mg (6.04 μL)
Study: 23273522
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg/day and bevacizumab 15 mg/kg every 3 weeks until progression
Study: 23274395
Drug: Liposomal-encapsulated docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal-encapsulated docetaxel (LE-DT) at 132 mg/m(2)
Study: 23274395
Drug: Liposomal-encapsulated docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal-encapsulated docetaxel (LE-DT) at 110 mg/m(2)
Study: 23274395
Drug: Liposomal-encapsulated docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal-encapsulated docetaxel (LE-DT) at 85 mg/m(2)
Study: 23274902
Drug: Posttransplant antibody
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posttransplant antibody increase (DSA or autoantibodies)
Study: 23274902
Drug: No posttransplant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No posttransplant antibody increase
Study: 23274906
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of [6,6-²H₂]-glucose followed by ingestion of four eggs containing 23 g of labeled proteins
Study: 23277518
Drug: Volatile organic
Normalized name: coal tar pitch volatiles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volatile organic compounds (VOCs) in exhaled breath
Study: 23278639
Drug: Denileukin diftitox
Normalized name: Denileukin diftitox
DrugBank: Denileukin diftitox (DB00004)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Denileukin diftitox (DD) 18 μg/kg/day (days 1, 2) with CHOP (day 3) every 21 days for ≤ 6-8 cycles
Study: 23281876
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR 300-800 mg once daily
Study: 23281975
Drug: ABT-450/r (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-450/r (250 mg ABT-450 + 100 mg ritonavir) + ABT-333 (400 mg twice daily) + ribavirin (1000 to 1200 mg per day)
Study: 23281975
Drug: ABT-450/r (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-450/r (150 mg ABT-450 + 100 mg ritonavir) + ABT-333 (400 mg twice daily) + ribavirin (1000 to 1200 mg per day)
Study: 23283106
Drug: Standard curative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard curative whole gland therapy
Study: 23285253
Drug: Boosted protease
Normalized name: protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boosted protease inhibitors (PI/r)
Study: 23286772
Drug: MTX and
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX and anti-TNF treatment
Study: 23287861
Drug: Panobinostat at
Normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panobinostat at 30 mg 3 times a week (12 of 36 patients at 25 mg dose)
Study: 23288588
Drug: Low-dose IFN-α
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IFN-α therapy
Study: 23288588
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no IFN-α treatment)
Study: 23289822
Drug: Once-daily insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily insulin detemir (Group A)
Study: 23289822
Drug: Twice-daily insulin
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily insulin detemir (Group B)
Study: 23291945
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of PHiD-CV
Study: 23292236
Drug: BU pharmacokinetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: BU pharmacokinetics (PKs) in patients with GSTM1 null genotype
Study: 23292236
Drug: Gene-dosage effect
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene-dosage effect
Study: 23292756
Drug: BMI, leptin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMI, leptin, L/A ratio and CA 15-3
Study: 23299114
Drug: Broad-spectrum antibiotics
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broad-spectrum antibiotics (including macrolide antibiotics and penicillin V)
Study: 23299114
Drug: GPs with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: GPs with a prescription rate of 33.3% or higher
Study: 23299315
Drug: BiRd therapy
Normalized name: Bird pepper
DrugBank: Bird pepper (DB14262)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BiRd therapy (clarithromycin 500 mg twice daily, lenalidomide 25 mg daily on days 1 to 21 of a 28-day cycle, dexamethasone 40 mg weekly)
Study: 23299315
Drug: BiRd therapy
Normalized name: Bird pepper
DrugBank: Bird pepper (DB14262)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BiRd therapy
Study: 23299770
Drug: CF102 (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CF102 (1, 5, and 25 mg BID)
Study: 23302513
Drug: Hatha yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hatha yoga classes (2 weekly 60-minute sessions for 32 weeks)
Study: 23303450
Drug: STAT3 peptide
Normalized name: Peptide T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: STAT3 peptide inhibitor
Study: 23303512
Drug: Individual Burden
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual Burden of Illness Index for Depression (IBI-D) after 12-week citalopram treatment
Study: 23305037
Drug: Glimepiride treatment
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glimepiride treatment (1 mg/d, titrated to 2 mg/d and 4 mg/d)
Study: 23305475
Drug: Insulin analogues
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin analogues (insulin aspart, insulin detemir, biphasic insulin aspart 30)
Study: 23307766
Drug: Antivirals administered
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antivirals administered to 1041 (58%) patients; treatment was at the physician's discretion.
Study: 23314553
Drug: Copeptin ultra-sensitive
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copeptin ultra-sensitive (copeptin-us) ≥14 pmol/L and hs-cTnT ≥0.014 µg/L
Study: 23314553
Drug: Copeptin ultra-sensitive
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copeptin ultra-sensitive (copeptin-us) <14 pmol/L and hs-cTnT <0.014 µg/L
Study: 23314553
Drug: hs-cTnT ≥0.014
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-cTnT ≥0.014 µg/L alone
Study: 23314553
Drug: Copeptin ultra-sensitive
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copeptin ultra-sensitive (copeptin-us) ≥14 pmol/L added to hs-cTnT
Study: 23315343
Drug: Low-dose acetylsalicylic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose acetylsalicylic acid (75-325 mg)
Study: 23315343
Drug: Low-dose acetylsalicylic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose acetylsalicylic acid experienced patients
Study: 23315343
Drug: Low-dose acetylsalicylic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose acetylsalicylic acid naïve patients
Study: 23315905
Drug: Deficient 25(OH)D
Normalized name: vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deficient 25(OH)D levels (<30 nmol/L)
Study: 23315905
Drug: Inadequate 25(OH)D
Normalized name: 1α,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inadequate 25(OH)D levels (30-49.9 nmol/L)
Study: 23315905
Drug: High 25(OH)D
Normalized name: HIGH DENSITY POLYETHYLENE
Approvals — FDA: no, EMA: no, PMDA: no
Description: High 25(OH)D levels (>100 nmol/L)
Study: 23316779
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of CA4P at a dose of 27 or 36 mg/m2 for 4 consecutive weeks
Study: 23316779
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of CA4P
Study: 23318482
Drug: Lesogaberan (AZD3355)
Normalized name: Lesogaberan
DrugBank: Lesogaberan (DB11920)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lesogaberan (AZD3355) as an add-on to PPI therapy
Study: 23320604
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose [90Y-DOTA]-TOC (median: 2.4 GBq/cycle)
Study: 23320604
Drug: Intermediate dose
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate dose [90Y-DOTA]-TOC (median: 3.3 GBq/cycle)
Study: 23320604
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose [90Y-DOTA]-TOC (median: 6.7 GBq/cycle)
Study: 23320927
Drug: huKS-IL2 (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: huKS-IL2 (3.0 mg/m2 IV continuous infusion over 4 hours on days 2, 3, and 4) with cyclophosphamide (300 mg/m2 on day 1)
Study: 23320927
Drug: huKS-IL2 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: huKS-IL2 (various doses) with cyclophosphamide (300 mg/m2)
Study: 23321252
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of YM155 and alemtuzumab
Study: 23321953
Drug: RAD001 (everolimus)
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: RAD001 (everolimus) 70 mg administered orally on days 1 and 7 of a 3+7 daunorubicin+cytarabine chemotherapy regimen
Study: 23321953
Drug: RAD001 (everolimus)
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: RAD001 (everolimus) 70 mg
Study: 23325012
Drug: Once-monthly pegylated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-monthly pegylated epoetin Beta
Study: 23325902
Drug: Everolimus (oral),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (oral), starting at 3 mg/m2 per day, titrated to achieve trough concentrations of 5-15 ng/mL.
Study: 23325915
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of 2% nonoxynol-9 (N-9) gel
Study: 23325915
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of Normosol-R fluid alone (negative control)
Study: 23325915
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of Normosol-R with coital simulation and sigmoidoscopic biopsy (CS + BX)
Study: 23325920
Drug: L-lysine from
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-lysine from cooked white rice (CWR) at doses of 10, 15, and 19 mg·kg(-1)·d(-1)
Study: 23325920
Drug: L-lysine from
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-lysine from oven-browned cooked rice at a dose of 19 mg·kg(-1)·d(-1)
Study: 23327295
Drug: Haloperidol prophylaxis
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol prophylaxis (1 mg/8 h)
Study: 23328269
Drug: Continuation maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation maintenance pemetrexed therapy plus best supportive care (BSC)
Study: 23329066
Drug: AZD4877 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD4877 25 mg administered once-weekly for 3 weeks of each 4-week cycle until disease progression, death, unacceptable toxicity or withdrawal
Study: 23329066
Drug: AZD4877 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD4877 25 mg
Study: 23331739
Drug: Topical tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tacrolimus 0.1% ointment once daily for 12 weeks
Study: 23331739
Drug: Topical tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tacrolimus 0.1% ointment continued in open label extension for relapsing patients
Study: 23331739
Drug: Topical tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tacrolimus 0.1% ointment for perineal disease
Study: 23331739
Drug: Topical tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tacrolimus 0.1% ointment overall safety
Study: 23332165
Drug: Drug-eluting absorbable
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting absorbable metal scaffold (DREAMS)
Study: 23333219
Drug: TNF-α antagonists
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TNF-α antagonists (infliximab, etanercept, adalimumab)
Study: 23335740
Drug: Caspofungin 70
Normalized name: caspofungin 70 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin 70 mg QD
Study: 23335740
Drug: Caspofungin 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin 100 mg QD
Study: 23335740
Drug: Caspofungin 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin 150 mg QD
Study: 23335740
Drug: Caspofungin 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin 200 mg QD
Study: 23340184
Drug: Visible cerebral
Normalized name: Sus scrofa cerebral cortex preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visible cerebral NIRS oximetry with pre-specified treatment guidelines
Study: 23340271
Drug: Conventional medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medical therapies (CMTs)
Study: 23341526
Drug: Erlotinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib plus whole-brain radiation therapy (WBRT)
Study: 23343427
Drug: Moxifloxacin (Avelox®)
Normalized name: moxifloxacin Injection [Avelox]
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin (Avelox®) 400 mg once daily for a mean duration of 6.4 ± 1.9 days
Study: 23344123
Drug: Patients receiving
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving neuromuscular block reversal agents (66.6% of patients; neostigmine in 97%)
Study: 23344123
Drug: Patients not
Normalized name: Lamictal 25mg-100mg Tablet Starter Kit (For Patients Not Taking Enzyme-Inducing Drugs or Valproate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients not receiving neuromuscular block reversal agents
Study: 23344286
Drug: Pravastatin (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (dosage and duration not specified)
Study: 23348202
Drug: i.v. fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. fluid (15 ml kg(-1) in 30 min)
Study: 23348203
Drug: Subgluteal sciatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgluteal sciatic nerve block with 20 ml of ropivacaine 4.75 mg ml(-1)
Study: 23349326
Drug: Autologous bone
Normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous bone marrow-derived mesenchymal stromal cells (MSCs) - 1 million cells per kilogram, two intravenous infusions
Study: 23352199
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of valproate
Study: 23352429
Drug: bivalent rLP2086
Normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bivalent rLP2086 vaccine (120 μg doses at 0, 1, and 6 months)
Study: 23353804
Drug: Clinician assessment
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician assessment of oral changes according to NIH criteria
Study: 23353804
Drug: Clinician and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician and patient assessments of oral changes
Study: 23354509
Drug: Successful CPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful CPAP therapy (n = 16)
Study: 23354509
Drug: Unsuccessful CPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsuccessful CPAP therapy (n = 8)
Study: 23355673
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate 220 mg daily for 42 days
Study: 23355673
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg daily for 42 days
Study: 23355673
Drug: Nadroparin 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin 0.3 ml subcutaneously for 42 days
Study: 23358617
Drug: Darbepoetin (DAR)
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin (DAR) 500 μg once every 2 weeks for 12 weeks
Study: 23359181
Drug: Panitumumab (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panitumumab (9 mg/kg) followed by Irinotecan (350 mg/m²) every 21 days
Study: 23364011
Drug: 25(OH)D deficiency
Normalized name: vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25(OH)D deficiency (<10 ng/mL)
Study: 23364011
Drug: 25(OH)D insufficiency
Normalized name: 1α,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25(OH)D insufficiency (10.0-19.9 ng/mL)
Study: 23364011
Drug: 25(OH)D sufficiency
Normalized name: 1α,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25(OH)D sufficiency (≥20 ng/mL)
Study: 23364320
Drug: Traditional NSAID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional NSAID therapy
Study: 23369458
Drug: Thymoglobulin induction
Normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymoglobulin induction combined with early steroid reduction to 5 mg/day, low dose cyclosporine (C2 target of 600 to 800 ng/ml), and mycophenolic acid (MPA) therapy
Study: 23369458
Drug: Historical cohort
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical cohort treated with Thymoglobulin induction, conventional doses of cyclosporine and corticosteroids
Study: 23370599
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg nebulized iloprost
Study: 23372266
Drug: 3.5 mg
Normalized name: niacin 13.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 mg ZST
Study: 23375329
Drug: Intra-arterial infusion
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusion of autologous bone marrow concentrate
Study: 23375926
Drug: Yoga training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga training (twice-weekly 60-min sessions for 3 months)
Study: 23377438
Drug: Regadenoson (1.44
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regadenoson (1.44 μg/kg/h) during pVOC
Study: 23378284
Drug: Two 30-μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 30-μg doses of unadjuvanted, inactivated pH1N1 vaccine 21 days apart
Study: 23380277
Drug: Bafetinib 240
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bafetinib 240 or 360 mg po, administered twice with a 12-hour interval
Study: 23380715
Drug: Logistic regression
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Logistic regression model for predicting treatment resistance
Study: 23382117
Drug: (111)In-labeled mature
Normalized name: Camphor (natural)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (111)In-labeled mature DCs with additional intradermal vaccination
Study: 23385153
Drug: Follow-up at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up at 6 months after treatment
Study: 23385197
Drug: Trabectedin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabectedin (1.5 mg/m², intravenously over 24 hours, repeated every 21 days)
Study: 23388195
Drug: AS03-adjuvanted H1N1
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03-adjuvanted H1N1 pandemic vaccine